Immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have shown promising survival benefits and manageable safety in first-line treatment of patients with G/GEJ cancers in the CheckMate-64910, GEMSTONE-10111, and ORIENT-16 trials12. This evidence concerns the gene CD274 and cancer.